AMARIN CORP PLCUK AMRN
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-2.07
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $213.6M | -$38.8M | $120.9M | — | $459.3M |
| 2024 | $228.6M | -$82.2M | $81.4M | — | $486.2M |
| 2023 | $306.9M | -$59.1M | $165.5M | — | $552.1M |
| 2022 | $369.2M | -$105.8M | $242.5M | — | $595.3M |
| 2021 | $583.2M | $7.7M | $461.9M | — | $667.1M |
| 2020 | $614.1M | -$18.0M | $482.6M | -$22.0M | $627.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Bonfiglio Patrice Eadon | director | 2026-04-18 | Tax withheld | 403 | $14.98 |
| Cohen Paul | director | 2026-04-18 | Option exercise | 838 | — |
| Cohen Paul | director | 2026-04-18 | Tax withheld | 403 | $14.98 |
| Sterling Louis III | director | 2026-04-18 | Option exercise | 838 | — |
| Sterling Louis III | director | 2026-04-18 | Tax withheld | 403 | $14.98 |
| Odysseas Kostas D | director | 2026-04-18 | Option exercise | 838 | — |
| Odysseas Kostas D | director | 2026-04-18 | Tax withheld | 403 | $14.98 |
| Bonfiglio Patrice Eadon | director | 2026-04-18 | Option exercise | 838 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.07 (distress)
- Working capital / assets 0.679
- Retained earnings / assets -2.545
- EBIT / assets -0.075
- Equity / liabilities 2.172
Source: SEC EDGAR filings · CIK 0000897448 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.